Teams reported AI models capable of designing complete bacteriophage genomes de novo, enabling rapid in‑silico construction of phage candidates. The work, covered by BioTecNika, demonstrates how generative models can accelerate viral genome design for therapeutic phage discovery but raises new biosecurity and governance questions about synthetic viruses. Authors showed model‑guided design can produce candidate phages with predicted host range and structural features, shortening lead‑generation timelines compared with traditional wet‑lab screening. The papers stress that lab validation and containment frameworks remain essential: computational design alone does not equate to safe, deployable therapeutics. For biotech firms and regulators, the development pressures tradeoffs between speed of biologic discovery and the need for oversight on dual‑use synthetic biology. Stakeholders will need technical standards, access controls and risk assessment pipelines to integrate AI‑driven design into regulated therapeutics workflows.